1Department of Internal Medicine, Bilecik State Hospital, Turkey
2Department of Endocrinology and metabolism, Bilecik State Hospital, Turkey
*Corresponding author: Mehmet Çelik, Department of Endocrinology and metabolism, Bilecik State Hospital, Turkey
Submission: April 02, 2018; Published: April 27, 2018
ISSN 2637-8019Volume2 Issue1
Diabetes mellitus is increasingly diagnosed today. In the treatment of diabetes mellitus, insulin and many oral anti-diabetic agents are used. With the increasing understanding of the pathophysiology of diabetes mellitus today, new pharmacological drugs are being developed and marketed for the use of patients in the treatment of diabetes. SGLT2 inhibitors from top-grade antidiabetic agents were used in the last decade for the use of patients diagnosed with diabetes and one of the newer generation drugs with different mechanisms of action. However, studies and case-reports suggesting that this drug group may increase the risk of euglycemic diabetic ketoacidosis. F.D.A (Food and Drug Administration) a warning was issued by May 2015. In this article we aimed to investigate the relationship between SGLT-2 inhibitors and diabetic ketoacidosis and to show that further data collection and study in this regard and appropriate follow-up are warranted.
Keywords: Euglycemic diabetic ketoacidosis; SGLT-2 inhibitors